Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Pembrolizumab/Lenvatinib Plus Chemo May Represent “Powerful” Option for NSCLC

April 20th 2022

Roy S. Herbst, MD, PhD, discusses the rationale for exploring immunotherapy/TKI combinations like pembrolizumab plus lenvatinib in patients with non–small cell lung cancer, and outlined the different efforts that comprise the LEAP clinical trial program.

HER2-Targeted CAR Macrophage CT-0508 Under Exploration in Solid Tumors with HER2 Overexpression

April 19th 2022

The safety, tolerability, and preliminary efficacy of the anti-HER2 CAR macrophage therapy, CT-0508, will be investigated in patients with solid tumors and HER2 overexpression, as part of a first-in-human phase 1 study.

Second Line T-DM1 Worsens Outcomes for HER2+ Breast Cancer in Real-World Study

April 19th 2022

Trastuzumab emtansine as a second-line treatment led to shorter median treatment duration and time to treatment failure in patients with HER2-positive metastatic breast cancer who progressed on pertuzumab and trastuzumab–based regimens.

Bortezomib Improves OS in Newly Diagnosed T-Cell Lymphoblastic Leukemia and Lymphoma

April 18th 2022

The addition of bortezomib to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma, according to data from the phase 3 AALL1231 trial.

Resistance to Noncovalent BTK Inhibitors Raises Questions Around Impact of Mutations in CLL

April 14th 2022

A small proportion of a subset of patients with chronic lymphocytic leukemia acquired mechanisms of genetic resistance to the novel noncovalent BTK inhibitor pirtobrutinib, according to results from a genomic analysis of patients in the phase 1/2 BRUIN trial.

BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma

April 12th 2022

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL

April 12th 2022

The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.

Off-the-Shelf Anti-Mesothelin CAR T-cell Therapy Improves In Vivo Activity Vs Gavo-Cel in Mesothelin-Expressing Tumors

April 10th 2022

Off-the-shelf anti-mesothelin T-cell receptor fusion construct T cells demonstrated prolonged persistence and efficacy in vivo against mesothelin-expressing tumors in mice, compared with gavocabtagene autoleucel.

Trilaciclib Before Chemo Results in Real-World Reduction of Myelosuppressive Hematologic AEs in ES-SCLC

April 7th 2022

The use of trilaciclib prior to chemotherapy resulted in a 50% reduction in the percent of patients with extensive-stage small cell lung cancer who had grade 3 or higher myelosuppressive hematologic adverse effects in at least 1 blood cell lineage.

Venetoclax Consolidation Does Not Prevent Loss of MRD Response Following First-Line Venetoclax/Obinutuzumab for CLL

April 7th 2022

Venetoclax consolidation following first-line treatment with venetoclax and obinutuzumab did not reduce loss of minimal residual disease response vs MRD-guided venetoclax consolidation in previously untreated patients with chronic lymphocytic leukemia.

Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC

April 1st 2022

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.

Patritumab Deruxtecan Shows Early Potential in Second-Line EGFR Inhibitor–Resistant, EGFR+ NSCLC

March 31st 2022

The newer generation antibody-drug conjugate patritumab deruxtecan has elicited encouraging responses with acceptable safety in patients with EGFR TKI–resistant, EGFR-mutated non–small cell lung cancer—a difficult-to-treat population with an unmet medical need.

NDA Resubmitted to FDA for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors

March 24th 2022

A new drug application for a unique formulation of sodium thiosulfate was resubmitted to the FDA for the second time for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have localized, nonmetastatic, solid tumors.

Adjunct Treatment With Uproleselan Could Enhance Effects of Chemotherapy in AML

March 23rd 2022

David Sallman, MD, provides perspective on the novel agent uproleselan, its efficacy in a phase 1/2 trial, and its investigation in phase 3 trials in acute myeloid leukemia.

Olaparib Shows Comparable OS to Chemotherapy in BRCA+, Platinum-Sensitive, Relapsed Ovarian Cancer

March 19th 2022

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

Olaparib Maintenance After Response to First-Line Chemo Under Exploration in BRCA Wild-Type Advanced Ovarian Cancer

March 18th 2022

Maintenance therapy with olaparib will be examined in patients with BRCA1/2 wild-type advanced ovarian cancer who responded to first-line, platinum-based chemotherapy in the phase 3 MONO-OLA1 trial.

Toripalimab/Chemo Combo Provides Significant Survival Benefit in NSCLC Without EGFR/ALK Mutations

March 16th 2022

The addition of toripalimab to chemotherapy resulted in improved progression-free survival and overall survival vs chemotherapy alone in patients with treatment-naïve advanced non–small cell lung cancer without EGFR or ALK mutations.

ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer

March 15th 2022

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

Sugemalimab Shows Efficacy as Consolidation Therapy in Unresectable Stage III NSCLC

March 11th 2022

Sugemalimab significantly prolonged progression-free survival (PFS) vs placebo in Chinese patients with locally advanced, unresectable, stage III non–small cell lung cancer who did not progress after concurrent or sequential chemoradiotherapy.

Sintilimab/Anlotinib Produces Meaningful Responses in PD-L1+ Recurrent or Metastatic Cervical Cancer

March 11th 2022

The addition of anlotinib to sintilimab appeared to be efficacious and safe when used as a second- or later-line treatment in patients with PD-L1–positive, recurrent or metastatic cervical cancer.